Complete if Known Substitute for form 1449A/PTO (Modified) Application Number 10/517.564 INFORMATION DISCLOSURE Filing Date December 15, 2005 STATEMENT BY APPLICANT DeKoning et al. First Named Inventor 1614---Art Unit 1623 (use as many sheets as necessary) Examiner Name Lawrence E. Crane 2 Docket 067670-5004-US Attorney Docket Number Sheet

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	A1							

FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶				
	B1									

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	Broeders et al. "A ³¹ P NMR Stereochemical and Kinetic Study of the Alkaline Hydrolysis of <i>cis</i> -Nucleoside 3',5'-Cyclic Aryl [¹⁸ 0]Monophosphates and Unlabled Analogs", <i>Amer Chem Society</i> (1992), Vol 114, no. 24, pp 9624-9633	
**	C2	Caesar accession number 1151, AN: 131:32132 CA "Adenosine 3',5'-cyclic	
		phosphates for treatment of ischemic diseases, and for organ preservation	
		Cassar accession number 1152, AN: 128-53046 CA "Skin Cosmetics"	
**		Caesar accession number 1153. AN: 115:159682 CA " N6,2'-O-Di-	
***************************************	-Gt	substituted-adenosine-3',5'-cyclic phosphates and their preparation	
**	CE	Caesar accession number 1155, AN: 114:102710 CA " N6,2'-O-Di-	
	nderditransanan	substituted-adenosine-3 ,5 -cyclic phosphates and their preparation	
		Caesar accession number 1796, AN: 96:143250 CA "Carbon-13 NMR	
jtrejt		spectrum of 2'-fluoro-2'-deoxyadenosine 3',5'-cyclic phosphate	-
		Ceasar accession number 1154, AN:114:143938 CA "Prepartion of	
**		N6,N6,2'-O-trisubstituted-adenosine-3',5'-cyclic phosphate as drugs	

Examiner Signature	/Lawrence Crane/	Date Considered	03/18/2010	

*EXAMINER: † These references were previously cited in a related application relied upon for an earlier filing date under 35 USC 120 and no copies are

"EXAMINER: † These references were previously cited in a related application relief upon for an earner ming date under 35 USO. 124 will not policy say submitted in a conformance with MPPF 1980. This will reference considered, whether on not citation is in conformance with MPPF 1990. Draw line through citation in for in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants insure citation designation number (options). "See Kinds Cobore of USPTO Patient Documents at www.upplo.gov or MPPF 901 04." Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patient document, the indication of the year of the register must procede the senial number of the patient document." Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.3. "For Japanese patient document, styling appropriate symbols as indicated on the document under WIPO Standard ST.3."

must precede the sector further of the patient document. "Mod of occurrent by the appropriate symbols as indicated on the document under WIPO Standard ST 161 possible." Applicant is to place of check mark here if Registe Language Transitation is attacked.

This collection of information is required by 37 CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is 161 file (and by the USFTO to process) an application. Or confidentially operated by 35 USF C22 and 37 CFR 1 14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark. Office, P.O. Box 1450, Alexandra, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

**Incomplete citation: No date of publication or original published source, etc.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.C./

					Approved for use through 03/31/2007	
	Substitute for fo		A/PTO	Complete if Known		
	(Modi	fied)		Application Number	10/517,564	
IN	FORMATION	DIS	CLOSURE	Filing Date	December 15, 2005	
S.	STATEMENT BY APPLICANT			First Named Inventor	DeKoning et al.	
				Art Unit	1614	
	(use as many sheets as necessary)			Examiner Name	Lawrence E. Crane	
Sheet	2	of	2	Attorney Docket Number	Docket 067670-5004-US	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶			
	C8	Ichiba et al. "Characterization of GFR, a novel guanine nucleotide exchange factor for Rap1" FEBS Letters (1999) Vol. 457:85-89				
	C9	McPhee et al. "Use of an activiation-specific probe to show that Rap1A and Rap1B display different sensitivities to activation for forskolin in Rat1 cells" FEBS Letters (2000) Vol. 477: 213-218				
	C10	Rooij et al. "Epac is a Rap 1 quanine-nucleotide-exchange factor directly activated by cyclic AMP" Nature (1998) Vol. 396: 474-477				

1-SF/7631038.1

Examiner Signature	/Lawrence Crane/	Date Considered	03/18/2010	

if you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.C./

Signature | ILASTIFCHICO OF CITET | ILASTIFCHICO OF CI